Orient Bio

Orient Bio Profit per Employee

The Profit per Employee of Orient Bio (002630.KS) as of Oct 28, 2026 is -38.06 M KRW. In the previous year, Profit per Employee was -109.96 M KRW — a change of -65.39% (higher).

Profit per Employee

-38.06 MKRW

YoY

-65.39%

Last updated:

Profit per Employee of Orient Bio is 2026 -38.06 M KRW. Profit per Employee of Orient Bio was 2025 -109.96 M KRW. It decreases by -65.39% higher compared to the previous year.

The Orient Bio Profit per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Profit per Employee
Date
Profit per Employee
Jan 1, 2019
-162.55 M KRW
Jan 1, 2020
-90.67 M KRW
Jan 1, 2021
-127.29 M KRW
Jan 1, 2022
284.98 M KRW
Jan 1, 2023
-103.53 M KRW
Jan 1, 2024
107.26 M KRW
Jan 1, 2025
-109.96 M KRW
Jan 1, 2026
-38.06 M KRW
The Orient Bio Profit per Employee history
YEARProfit per EmployeeYoY
-38.06 MKRW-65.39%
-109.96 MKRW-202.52%
107.26 MKRW-203.60%
-103.53 MKRW-136.33%
284.98 MKRW-323.88%
-127.29 MKRW+40.39%
-90.67 MKRW-44.22%
-162.55 MKRW+40.68%
-115.54 MKRW-27.51%
-159.39 MKRW+535.59%
-25.08 MKRW+72.04%
-14.58 MKRW-81.69%
-79.59 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Orient Bio Stock analysis

What does Orient Bio do? Orient Bio Inc generates revenue through the production and supply of laboratory animals such as mice, rats, guinea pigs, hamsters, SPF rabbits, and beagles. The company also offers CRO services including safety assessments and new drug development, alongside medical and library equipment like barrier systems. Additional income comes from support services such as rodent surgery, laboratory diagnostics, transgenic services, and genetic testing. The firm further provides feeds, reagents, disinfectants, automobile components, power supply equipment, and other machines through its subsidiaries. Orient Bio Inc's primary customers include research institutions, pharmaceutical companies, and medical facilities requiring laboratory animals and specialized services. The company's product segments consist of live animals, CRO services, medical equipment, and ancillary products like feeds and reagents. Subsidiaries contribute to revenue by supplying complementary items such as disinfectants and power supply equipment. The business model leverages a diversified portfolio of biotechnology products and services, targeting both direct research and development needs and ancillary support requirements. Revenue streams are derived from the sale of animals, provision of CRO services, equipment sales, and subsidiary product lines, ensuring steady income across multiple segments. Orient Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Orient Bio stock

Profit per Employee of Orient Bio is -38.06 M KRW in 2026.

Profit per Employee of Orient Bio changed from -109.96 M KRW to -38.06 M KRW, representing a -65.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Profit per Employee Orient Bio since 2006 – with annual values, charts, and detailed analysis.

Profit per employee measures how much net income each employee generates on average. It is a key indicator of workforce efficiency.

Profit per Employee's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Profit per Employee's Orient Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Orient Bio

All Key Metrics — Orient Bio